Abstract
Mistletoe lectin I (ML-I) is a heterodimeric ribosome-inactivating protein composed of a sialic acid-specific Bchain that binds to cell surfaces, and an A-chain with the capacity to depurinate a critical adenosine in the 28S ribosomal RNA. ML-1, in purified or recombinant form, exerts an immunomodulatory effect on neutrophils and macrophages/ monocytes in the low-dose range, while at high doses, it induces apoptosis in both normal and tumoral cells. While mistletoe extracts are widely used as cancer adjuvant therapy, recombinant ML-I (rAviscumin) is a candidate antineoplastic agent that has successfully passed Phase I clinical trials. In immunodeficient mouse models, the efficacy of recombinant ML-I was demonstrated for ovarian carcinoma, melanoma and various hematological malignant cell lines. The clinical potential of recombinant ML-I as a non-mutagenic and non-genotoxic molecule is high and could be used to potentiate classical anti-neoplastic drugs. Its capacity to induce apoptosis in cancer cell lines lacking p53 allows considering its use against genetically unstable and highly metastatic cancers. The mechanisms of apoptosis induced by ML-I probably involves intracellular pathways akin to those described as the “ribotoxic stress response” that directly target the mitochondrion.
Current Organic Chemistry
Title: Mistletoe Lectins: Carbohydrate-Specific Apoptosis Inducers and Immunomodulators
Volume: 12 Issue: 11
Author(s): Daniel C. Hoessli and Ishtiaq Ahmad
Affiliation:
Abstract: Mistletoe lectin I (ML-I) is a heterodimeric ribosome-inactivating protein composed of a sialic acid-specific Bchain that binds to cell surfaces, and an A-chain with the capacity to depurinate a critical adenosine in the 28S ribosomal RNA. ML-1, in purified or recombinant form, exerts an immunomodulatory effect on neutrophils and macrophages/ monocytes in the low-dose range, while at high doses, it induces apoptosis in both normal and tumoral cells. While mistletoe extracts are widely used as cancer adjuvant therapy, recombinant ML-I (rAviscumin) is a candidate antineoplastic agent that has successfully passed Phase I clinical trials. In immunodeficient mouse models, the efficacy of recombinant ML-I was demonstrated for ovarian carcinoma, melanoma and various hematological malignant cell lines. The clinical potential of recombinant ML-I as a non-mutagenic and non-genotoxic molecule is high and could be used to potentiate classical anti-neoplastic drugs. Its capacity to induce apoptosis in cancer cell lines lacking p53 allows considering its use against genetically unstable and highly metastatic cancers. The mechanisms of apoptosis induced by ML-I probably involves intracellular pathways akin to those described as the “ribotoxic stress response” that directly target the mitochondrion.
Export Options
About this article
Cite this article as:
Hoessli C. Daniel and Ahmad Ishtiaq, Mistletoe Lectins: Carbohydrate-Specific Apoptosis Inducers and Immunomodulators, Current Organic Chemistry 2008; 12 (11) . https://dx.doi.org/10.2174/138527208784892196
DOI https://dx.doi.org/10.2174/138527208784892196 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Advances of Heterocyclic Chemistry with Pesticide Activity
Global food safety and security will continue to be a global concern for the next 50 years and beyond. Plant diseases have had a significant impact on food safety and security throughout the entire food chain, from primary production to consumption. While conventional chemical pesticides have been traditionally used for ...read more
Calculation design of covalent/metal organic framework based catalysts
This research area combines theoretical computation and screening with machine learning for the design of covalent/metal organic framework-based catalysts, bridging the disciplines of organic chemistry, physical chemistry, computational chemistry, materials science, and machine learning. It covers several critical aspects: designing and synthesizing organic catalysts for improved performance, applying computational methods ...read more
Carbohydrates conversion in biofuels and bioproducts
Biomass pretreatment, hydrolysis, and saccharification of carbohydrates, and sugars bioconversion in biofuels and bioproducts within a biorefinery framework. Carbohydrates derived from woody biomass, agricultural wastes, algae, sewage sludge, or any other lignocellulosic feedstock are included in this issue. Simulation, techno-economic analysis, and life cycle analysis of a biorefinery process are ...read more
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets Functional Role of miR-34 Family in Human Cancer
Current Drug Targets DNA Methyltransferase Inhibitors and their Therapeutic Potential
Current Topics in Medicinal Chemistry The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Synthesis of Pyridine and Spiropyridine Derivatives Derived from 2-aminoprop- 1-ene-1,1,3-tricarbonitrile Together with their c-Met Kinase and Antiproliferative Evaluations
Anti-Cancer Agents in Medicinal Chemistry Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design Immunomodulatory Drugs as a Therapy for Multiple Myeloma
Current Pharmaceutical Biotechnology The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Drug Resistance in Childhood Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
Reviews on Recent Clinical Trials The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin
Pharmaceutical Nanotechnology 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry